The Corona Remedies IPO is a highly anticipated offering from pharmaceutical manufacturer Corona Remedies Ltd., which has generated significant market attention and investor enthusiasm. Corona Remedies will finalize the share allotment on Thursday, December 11. Investors who applied will receive messages, alerts, or emails regarding the money being debited or their IPO mandate being released by Friday, December 12, at the latest, or by the weekend. Overall, the IPO received a decent but not very strong response.
Here’s everything you need to know in one place. We’ll explain the remaining details in this blog to help investors understand the IPO better.
Corona Remedies IPO Overview
- Company: Corona Remedies Ltd was founded on August 27, 2004. It began as Corona Remedies Private Limited and was later converted into a public limited company in 2024.
- Issue Type: Book-built IPO, fully Offer for Sale (OFS) of existing shareholders
- Issue Size: About ₹655.37 crore
- Price Band: ₹1,008 to ₹1,062 per share
- Lot Size: 14 shares per lot
- Minimum Investment: Around ₹14,868 at the upper price band
Corona Remedies is an Ahmedabad-based pharma company that develops and sells products across key areas such as women’s health, cardiology, pain relief, urology, and more. The company offers 71 brands and has a large field force of 2,671 medical representatives working across 22 states.
Corona Remedies IPO Application Status
The Corona Remedies IPO received overwhelming interest during its subscription window, from December 8 to December 10. Priced between ₹1,008 and ₹1,062 per share with a lot size of 14 shares, the company raised ₹655.37 crore through a complete offer-for-sale of 61,71,101 shares.
In terms of applications, the IPO saw very high demand, being subscribed 137.04 times with bids worth over ₹66,500 crore and more than 41.87 lakh applications. QIBs subscribed 278.52 times, NIIs 208.88 times, while retail investors and employees subscribed 28.73 times and 14.72 times, respectively.
IPO Schedule & Important Dates
| Event | Date |
| IPO Opens | 8 Dec 2025 |
| IPO Closes | 10 Dec 2025 |
| Allotment Finalization | 11 Dec 2025 |
| Refunds & Demat Credit | 12 Dec 2025 |
| Expected Listing Date | 15 Dec 2025 |
The IPO attracted strong interest from all investor categories, with the issue being subscribed more than 18.5 times by the final day, far exceeding the number of shares available. Despite this high demand, allotment for individual investors will still depend on their specific category and the total number of applications submitted.
IPO Allotment Chances for Retail and HNI Investors
For investors, the allotment chances vary by category:
- Big HNIs: Only about 1 out of every 50 applicants is likely to receive 196 shares, giving a 2% chance of allotment.
- Small HNIs: Around 1 in 158 applicants may get 196 shares, which means a very low 0.63% chance.
- Retail Investors: Approximately 1 out of 23 applicants is expected to receive 14 shares, giving a 4.35% chance of allotment.
These numbers show that the competition was extremely high across all categories.
Grey Market Premium (GMP) & Listing Expectations
GMP Summary Table
| Detail | Information |
| Current GMP | ₹295–₹300 per share |
| Estimated Listing Gain | Around 28% |
| GMP During Bidding Phase | ₹250–₹260 |
| Market Sentiment | Muted overall, but GMP is improving |
| Lead Managers | JM Financial, IIFL Capital, Kotak Mahindra Capital |
| Registrar | Bigshare Services |
| Refunds / Demat Credits | December 12 |
| Expected Listing Date | December 15 |
| Listing Exchanges | BSE & NSE |
1. GMP Strengthening
The grey market premium for Corona Remedies has been rising steadily, supported by strong subscription numbers and consistent listing performance across the market, even though overall sentiment remains on the quieter side.
2. Latest GMP Range
The most recent GMP stands in the ₹295–₹300 band, reflecting firm investor interest and optimistic expectations ahead of the listing.
3. Expected Listing Gain
Based on the current GMP trend, analysts expect the stock to list with an estimated 28% premium. Although the GMP reflects market sentiment, it is unofficial and does not guarantee the actual listing outcome.
4. Earlier GMP Movement
During the IPO subscription window, the grey market premium stayed in the ₹250–₹260 range, indicating that demand has strengthened noticeably as the issue progressed.
5. Lead Managers
The IPO is being led by seasoned book-running lead managers — JM Financial, IIFL Capital, and Kotak Mahindra Capital — adding credibility to the overall process.
6. Registrar Details
Bigshare Services is overseeing the allotment procedures, refund initiation, and coordination with investors for the offering.
7. Refunds & Credit Timeline
The authorities will complete refunds and demat share credits on December 12 as per the scheduled timeline.
8. Listing Date
Corona Remedies will debut on the BSE and NSE on December 15.
How to Check the Corona Remedies IPO Allotment Status?
Investors who applied for the Corona Remedies IPO can verify their allotment status through the Bombay Stock Exchange (BSE) website or the Bigshare Services portal, the official registrar for the issue.
1. Checking Allotment Status on the BSE Website
Follow these steps to view your status on the BSE portal:
- Visit the official BSE allotment page: https://www.bseindia.com/investors/appli_check.aspx
- Under Issue Type, select Equity
- In the Issue Name dropdown, choose Corona Remedies Limited
- Enter your Application Number
- Provide your PAN Details
- Tick the ‘I am not a Robot’ verification box
- Click on Search to view your allotment status
2. Checking Allotment Status on Bigshare Services (Registrar Portal)
Investors can also access the allotment status through the Bigshare Services website: https://ipo.bigshareonline.com/IPO_Status.html
Registrar Role (as per SEBI Guidelines)
Bigshare Services Limited, a SEBI-registered registrar, manages the electronic processing of IPO applications, conducts the allotment, updates the credit of shares to successful bidders, processes refunds, and handles all investor-related communication.
Steps to Check Via Bigshare Services
- Visit the Bigshare Services IPO status page
- Select the Corona Remedies IPO from the dropdown (it appears only after the allotment is finalized).
- Choose any one search method:
- Application Number / CAF No, or
- DP/Beneficiary ID, or
- PAN Number
- Fill the details based on your selected option
- Complete the captcha for security verification
- Click Search to view your allotment result
FAQs
Q1. What is the GMP of the Corona Remedies IPO?
Ans. As per various media sources, the grey market premium for the Corona Remedies IPO is currently around ₹270 above the issue price.
Q2. Is Corona Remedies a good IPO?
Ans. The company’s financial performance reflects solid growth, with revenues rising 18% year-on-year and profit after tax jumping 65%. Its consistent market presence and a valuation of around 35x P/E make analysts optimistic about both potential listing gains and long-term investment prospects.
Q3. How is IPO allotment status checked?
Ans. Investors can also verify their allotment status through the websites of various Registrar and Transfer Agents (RTAs). Some key RTAs include:
- MUFG Intime: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
- Bigshare Services: https://www.bigshareonline.com/ipo_Allotment.html
Q4. Is IPO allotment fair?
Ans. Yes, IPO allotment is generally fair and regulated, using a lottery system for retail investors and proportionate allocation for HNIs, though success also depends on luck and correct application details.
